FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006286039> ?p ?o ?g. }

• W2006286039 endingPage "824" @default.
• W2006286039 startingPage "816" @default.
• W2006286039 abstract "Gonadotropin-releasing hormone agonists (GnRHa) are associated with greater risk of coronary heart disease and myocardial infarction in men with prostate cancer, but little is known about their potential effects on cardiovascular mortality. We assessed the relationship between duration of GnRHa therapy and cardiovascular mortality in a large randomized trial of men treated with short-term versus longer-term adjuvant goserelin and radiation therapy (RT) for locally advanced prostate cancer. From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c–4, prostate-specific antigen [PSA] <150 ng/ml) received RT and 4 mo of goserelin and then were randomized to no additional therapy (arm 1) or 24 mo adjuvant goserelin (arm 2) in a phase 3 trial (Radiation Therapy Oncology Group [RTOG] 92-02). Cox regression analyses were performed to evaluate the relationship between treatment arm and cardiovascular mortality. Covariates included age, prevalent cardiovascular disease (CVD), hypertension, diabetes (DM), race, PSA, Gleason score, and stage. After median follow-up of 8.1 yr, 185 cardiovascular-related deaths had occurred. No increase in cardiovascular mortality occurred for men receiving a longer duration of goserelin. At 5 yr, cardiovascular mortality for men receiving longer-term adjuvant goserelin was 5.9% versus 4.8% with short-term goserelin (Gray's p = 0.16). In multivariate analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality (adjusted hazard ratio [HR] = 1.09; 95% confidence interval [CI], 0.81–1.47; p = 0.58; when censoring at time of salvage goserelin, HR = 1.02, 95%CI, 0.73–1.43; p = 0.9). Traditional cardiac risk factors, including age, prevalent CVD, and DM, were significantly associated with greater cardiovascular mortality. Longer duration of adjuvant GnRHa therapy does not appear to increase cardiovascular mortality in men with locally advanced prostate cancer." @default.
• W2006286039 created "2016-06-24" @default.
• W2006286039 creator A5005714909 @default.
• W2006286039 creator A5012866369 @default.
• W2006286039 creator A5017925159 @default.
• W2006286039 creator A5045162411 @default.
• W2006286039 creator A5048513152 @default.
• W2006286039 creator A5059111432 @default.
• W2006286039 creator A5089628955 @default.
• W2006286039 date "2008-10-01" @default.
• W2006286039 modified "2023-10-06" @default.
• W2006286039 title "Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02" @default.
• W2006286039 cites W1969965083 @default.
• W2006286039 cites W1972939339 @default.
• W2006286039 cites W1993493061 @default.
• W2006286039 cites W1997732940 @default.
• W2006286039 cites W2000038887 @default.
• W2006286039 cites W2019530713 @default.
• W2006286039 cites W2050743117 @default.
• W2006286039 cites W2066899660 @default.
• W2006286039 cites W2073140442 @default.
• W2006286039 cites W2074421032 @default.
• W2006286039 cites W2082541377 @default.
• W2006286039 cites W2088834583 @default.
• W2006286039 cites W2098998490 @default.
• W2006286039 cites W2106194496 @default.
• W2006286039 cites W2106458814 @default.
• W2006286039 cites W2128365260 @default.
• W2006286039 cites W2129509910 @default.
• W2006286039 cites W2144498681 @default.
• W2006286039 cites W2148386014 @default.
• W2006286039 cites W2158397011 @default.
• W2006286039 cites W2162514583 @default.
• W2006286039 cites W2165990809 @default.
• W2006286039 cites W2306070430 @default.
• W2006286039 cites W2337912524 @default.
• W2006286039 doi "https://doi.org/10.1016/j.eururo.2008.01.021" @default.
• W2006286039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18243498" @default.
• W2006286039 hasPublicationYear "2008" @default.
• W2006286039 type Work @default.
• W2006286039 sameAs 2006286039 @default.
• W2006286039 citedByCount "187" @default.
• W2006286039 countsByYear W20062860392012 @default.
• W2006286039 countsByYear W20062860392013 @default.
• W2006286039 countsByYear W20062860392014 @default.
• W2006286039 countsByYear W20062860392015 @default.
• W2006286039 countsByYear W20062860392016 @default.
• W2006286039 countsByYear W20062860392017 @default.
• W2006286039 countsByYear W20062860392018 @default.
• W2006286039 countsByYear W20062860392019 @default.
• W2006286039 countsByYear W20062860392020 @default.
• W2006286039 countsByYear W20062860392021 @default.
• W2006286039 countsByYear W20062860392022 @default.
• W2006286039 countsByYear W20062860392023 @default.
• W2006286039 crossrefType "journal-article" @default.
• W2006286039 hasAuthorship W2006286039A5005714909 @default.
• W2006286039 hasAuthorship W2006286039A5012866369 @default.
• W2006286039 hasAuthorship W2006286039A5017925159 @default.
• W2006286039 hasAuthorship W2006286039A5045162411 @default.
• W2006286039 hasAuthorship W2006286039A5048513152 @default.
• W2006286039 hasAuthorship W2006286039A5059111432 @default.
• W2006286039 hasAuthorship W2006286039A5089628955 @default.
• W2006286039 hasConcept C121608353 @default.
• W2006286039 hasConcept C126322002 @default.
• W2006286039 hasConcept C126894567 @default.
• W2006286039 hasConcept C143998085 @default.
• W2006286039 hasConcept C207103383 @default.
• W2006286039 hasConcept C2777899217 @default.
• W2006286039 hasConcept C2778043895 @default.
• W2006286039 hasConcept C2780192828 @default.
• W2006286039 hasConcept C44249647 @default.
• W2006286039 hasConcept C50382708 @default.
• W2006286039 hasConcept C509974204 @default.
• W2006286039 hasConcept C71924100 @default.
• W2006286039 hasConceptScore W2006286039C121608353 @default.
• W2006286039 hasConceptScore W2006286039C126322002 @default.
• W2006286039 hasConceptScore W2006286039C126894567 @default.
• W2006286039 hasConceptScore W2006286039C143998085 @default.
• W2006286039 hasConceptScore W2006286039C207103383 @default.
• W2006286039 hasConceptScore W2006286039C2777899217 @default.
• W2006286039 hasConceptScore W2006286039C2778043895 @default.
• W2006286039 hasConceptScore W2006286039C2780192828 @default.
• W2006286039 hasConceptScore W2006286039C44249647 @default.
• W2006286039 hasConceptScore W2006286039C50382708 @default.
• W2006286039 hasConceptScore W2006286039C509974204 @default.
• W2006286039 hasConceptScore W2006286039C71924100 @default.
• W2006286039 hasIssue "4" @default.
• W2006286039 hasLocation W20062860391 @default.
• W2006286039 hasLocation W20062860392 @default.
• W2006286039 hasOpenAccess W2006286039 @default.
• W2006286039 hasPrimaryLocation W20062860391 @default.
• W2006286039 hasRelatedWork W2318819988 @default.
• W2006286039 hasRelatedWork W2398122810 @default.
• W2006286039 hasRelatedWork W2466734156 @default.
• W2006286039 hasRelatedWork W2793295628 @default.
• W2006286039 hasRelatedWork W2896128085 @default.
• W2006286039 hasRelatedWork W3021633275 @default.
• W2006286039 hasRelatedWork W4220991042 @default.

• next